E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
To evaluate the long-term safety of LUM 0.01% compared with
LUM 0.03% administered once daily for 2 years in patients with
glaucoma or ocular hypertension |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 13.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020784 |
E.1.2 | Term | Hypertension ocular |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 13.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10015943 |
E.1.2 | Term | Eye inflammation |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the long-term safety of LUM 0.01% compared with
LUM 0.03% administered once daily for 2 years in patients with
glaucoma or ocular hypertension |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female, at least 18 years of age and of legal age of consent
2. Patient has either OHT, primary open-angle glaucoma, chronic angle-closure
glaucoma with patent iridotomy/iridectomy, pseudoexfoliative glaucoma, or
pigmentary glaucoma in each eye
3. Patient requires bilateral IOP-lowering therapy and his/her IOP is likely to be
controlled on bimatoprost monotherapy
4. Baseline: A best-corrected visual acuity score equivalent to a Snellen acuity of 20/100
or better in each eye, using a logarithmic visual acuity chart for testing at 10 feet
(3 meters)
5. Baseline: Negative urine pregnancy test for females of childbearing potential prior to
randomization
6. Written informed consent has been obtained prior to any study procedures
7. Patient is able and willing to follow study instructions and likely to complete all
required visits
8. Written documentation has been obtained in accordance with the relevant country and
local privacy requirements, where applicable (eg, written Data Protection consent
[sites in European Union]). |
|
E.4 | Principal exclusion criteria |
1. Uncontrolled systemic disease
2. Females who are pregnant, nursing, or planning a pregnancy or females of
childbearing potential, not using a reliable method of contraception. A female is
considered to be of childbearing potential unless she is without a uterus or is
post-menopausal and has been amenorrheic for at least 12 consecutive months.
3. Patients with advanced ocular surface disease (eg, dry eye) or in whom the cornea is
compromised
4. Previous suspected adverse reaction to either PGA or to BAK exposure that has led to
discontinuation of medication
5. Known allergy or hypersensitivity to the study medication or its components
6. Allergy or contraindication to the use of topical fluorescein, lissamine green or any
other diagnostic agent needed for study examination procedures
7. Active or recurrent ocular disease (eg, uveitis, ocular infections, chronic blepharitis,
or moderate to severe dry eye), that in the opinion of the investigator would interfere
with the interpretation of the study data
8. Known chronic exposure to causes of ocular surface irritation (eg, smoke, chlorine)
9. History of recurrent ocular seasonal allergies within the past 2 years
10. Qualification/baseline (day 1): Active ocular surface findings (such as hyperaemia,
irritation, dryness [including that associated with trabeculectomy blebs or drainage
tubes, such as corneal dellen, etc]) equal to +1 (mild) or greater in either eye found on
gross macroscopic hyperaemia or slit-lamp examination
11. Required chronic use of ocular medications during the study other than the study
medication. Note: Intermittent use of artificial tear products are allowed, but not
within 24 hours of a scheduled visit. Intermittent use of ocular decongestants or
antihistamines is allowed, but not within 2 weeks of a scheduled visit
12. Corneal or other ocular abnormalities that would preclude accurate readings with an
applanation tonometer
13. Patient’s IOP was previously uncontrolled on bimatoprost monotherapy
14. History of severe ocular trauma
15. History (within 3 months prior to qualification/baseline [day 1]) of ocular laser,
intraocular, filtering or refractive surgery or planned ocular surgery of any kind at
entry (qualification/baseline)
16. Visual field loss which in the opinion of the investigator is functionally significant or
evidence of progressive visual field loss within the year prior to qualification/baseline
(day 1)
17. Contraindication to pupil dilation
18. Anticipated wearing of contact lenses during the study (after signing informed
consent, use of soft lenses should be discontinued at least 2 days prior to
qualification/baseline [day 1], and use of rigid gas permeable [RGP] or hard contact
lenses should be discontinued at least 1 week prior to qualification/baseline [day 1])
19. Current enrollment in an investigational drug or device study or participation in such
a study within 30 days prior to qualification/baseline (day 1)
20. Patient has a condition or is in a situation which, in the investigator’s opinion, may
put the patient at a significant risk, may confound study results, or may interfere
significantly with the patient’s participation in the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Reports of one or more treatment-related adverse events associated with the ocular surface
will be the primary variable. The proportion of patients reporting treatment-related ocular
surface adverse events over the 2-year course of the study in each treatment group will be
calculated. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
- same IMP used at different dosage |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 50 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |